Breyna?

Breyna is a biosimilar to the biologic drug Symbicort [1]. Symbicort is a combination inhaler containing budesonide and formoterol [1]. It is used to prevent asthma attacks and reduce symptoms of chronic obstructive pulmonary disease (COPD) [1].

When can Breyna be prescribed for asthma?

Breyna is indicated for the maintenance treatment of asthma in patients aged 6 years and older [1]. It is not intended to relieve sudden asthma symptoms [1].

What is the difference between Breyna and Symbicort?

Breyna is a biosimilar to Symbicort [1]. This means that Breyna is highly similar to Symbicort and has no clinically meaningful differences in terms of safety, purity, and potency [1]. The U.S. Food and Drug Administration (FDA) approved Breyna based on evidence demonstrating its similarity to Symbicort [1].

How does Breyna work for COPD?

Breyna is also indicated for the maintenance treatment of airflow obstruction in patients with COPD and for the reduction of exacerbations in patients with COPD [1].

Who manufactures Breyna?

Breyna is manufactured by AstraZeneca [1].

How is Breyna administered?

Breyna is an orally inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination medication [1]. It is delivered via a Diskus inhaler [1].